GlassScriptPhysician profile
Michael A Nagel
NPI 1912999350
$8,813.46
in general payments reported to CMS, 2019-2025
66 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $410 · 2021: $922 · 2022: $902 · 2023: $1,198 · 2024: $1,740 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,196 · Education: $61.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,195.95 |
| Education | $61.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,637.77 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $892.27 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $773.56 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $473.47 | 2021-2025 | |
| Abbvie INC. | $369.40 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $309.83 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $271.09 | 2021-2025 | Vumerity, Tysabri, Spinraza |
| Alexion Pharmaceuticals, INC. | $263.77 | 2019-2024 | Ultomiris |
| Emd Serono, INC. | $246.94 | 2019-2025 | Mavenclad |
| Eisai INC. | $245.68 | 2019-2024 | |
| Piramal Critical Care | $231.87 | 2019-2025 | |
| Aquestive Therapeutics, INC. | $223.72 | 2019-2022 | |
| Biocodex, INC. | $179.18 | 2023-2025 | Diacomit |
| Jazz Pharmaceuticals INC. | $148.29 | 2023-2025 | Epidiolex |
| Genentech USA, INC. | $147.58 | 2020-2025 | Ocrevus Zunovo, Evrysdi, Enspryng |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nagel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.